Paul Freiman
Presidente presso NOVABAY PHARMACEUTICALS
Patrimonio netto: 137 $ in data 30/04/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Justin Hall | M | 46 | 11 anni | |
| Adel Karas | M | 79 | 17 anni | |
| John J. DiPietro | M | 65 |
Chronix Biomedical, Inc.
 Chronix Biomedical, Inc. Medical SpecialtiesHealth Technology Chronix Biomedical, Inc. manufactures diagnostic substances chemicals. It develops DNA-based blood tests primarily for monitoring minimal residual disease in cancer patients. The firm also develops a technology that measures personalized biomarkers in cancers of the colorectum, prostate, lung, ovarian, pancreas, blood and central nervous system. The company was founded by Wiiliam A. Boeger and Howard B. Urnovitz in 1997 and is headquartered in San Jose, CA. | 29 anni |
| Wiiliam A. Boeger | M | - |
Chronix Biomedical, Inc.
Chronix Biomedical, Inc. Medical SpecialtiesHealth Technology Chronix Biomedical, Inc. manufactures diagnostic substances chemicals. It develops DNA-based blood tests primarily for monitoring minimal residual disease in cancer patients. The firm also develops a technology that measures personalized biomarkers in cancers of the colorectum, prostate, lung, ovarian, pancreas, blood and central nervous system. The company was founded by Wiiliam A. Boeger and Howard B. Urnovitz in 1997 and is headquartered in San Jose, CA. | 27 anni |
| Kartlos Edilashvili | M | 50 | 17 anni | |
| Tommy Law | M | 38 | 5 anni | |
| Joshua Silverman | M | 53 | 8 anni | |
| Yen You Zheng | M | 67 | 5 anni | |
| Ekkehard Schütz | M | - |
Chronix Biomedical, Inc.
Chronix Biomedical, Inc. Medical SpecialtiesHealth Technology Chronix Biomedical, Inc. manufactures diagnostic substances chemicals. It develops DNA-based blood tests primarily for monitoring minimal residual disease in cancer patients. The firm also develops a technology that measures personalized biomarkers in cancers of the colorectum, prostate, lung, ovarian, pancreas, blood and central nervous system. The company was founded by Wiiliam A. Boeger and Howard B. Urnovitz in 1997 and is headquartered in San Jose, CA. | - |
| Julie Garlikov | F | 53 | 2 anni | |
| Zachary Chen | M | - |
Impressions Holdings LLC
 Impressions Holdings LLC Advertising/Marketing ServicesCommercial Services Impressions Holdings LLC operates as holding company whose subsidiaries provide media creation, software development, and lead generation services. The company was founded by Zachary Chen, Paul Freiman, and Gabriele Genghini in 2013 and is headquartered in San Francisco, CA. | - |
| Swan Sit | F | 46 | 5 anni | |
| David R. MacKenzie | M | - |
Chronix Biomedical, Inc.
Chronix Biomedical, Inc. Medical SpecialtiesHealth Technology Chronix Biomedical, Inc. manufactures diagnostic substances chemicals. It develops DNA-based blood tests primarily for monitoring minimal residual disease in cancer patients. The firm also develops a technology that measures personalized biomarkers in cancers of the colorectum, prostate, lung, ovarian, pancreas, blood and central nervous system. The company was founded by Wiiliam A. Boeger and Howard B. Urnovitz in 1997 and is headquartered in San Jose, CA. | - |
| Mike Jerstad | M | - |
Chronix Biomedical, Inc.
Chronix Biomedical, Inc. Medical SpecialtiesHealth Technology Chronix Biomedical, Inc. manufactures diagnostic substances chemicals. It develops DNA-based blood tests primarily for monitoring minimal residual disease in cancer patients. The firm also develops a technology that measures personalized biomarkers in cancers of the colorectum, prostate, lung, ovarian, pancreas, blood and central nervous system. The company was founded by Wiiliam A. Boeger and Howard B. Urnovitz in 1997 and is headquartered in San Jose, CA. | - |
| Philip E. Wolfson | M | 79 |
Phytos, Inc.
| 26 anni |
| Bob Wu | M | 49 | 8 anni | |
| Robert D. Leppo | M | - |
Chronix Biomedical, Inc.
Chronix Biomedical, Inc. Medical SpecialtiesHealth Technology Chronix Biomedical, Inc. manufactures diagnostic substances chemicals. It develops DNA-based blood tests primarily for monitoring minimal residual disease in cancer patients. The firm also develops a technology that measures personalized biomarkers in cancers of the colorectum, prostate, lung, ovarian, pancreas, blood and central nervous system. The company was founded by Wiiliam A. Boeger and Howard B. Urnovitz in 1997 and is headquartered in San Jose, CA. | - |
| Ralf Glaubitz | M | - |
Chronix Biomedical, Inc.
Chronix Biomedical, Inc. Medical SpecialtiesHealth Technology Chronix Biomedical, Inc. manufactures diagnostic substances chemicals. It develops DNA-based blood tests primarily for monitoring minimal residual disease in cancer patients. The firm also develops a technology that measures personalized biomarkers in cancers of the colorectum, prostate, lung, ovarian, pancreas, blood and central nervous system. The company was founded by Wiiliam A. Boeger and Howard B. Urnovitz in 1997 and is headquartered in San Jose, CA. | - |
| Sean Zheng | M | 54 | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Charles S. Ramat | M | 72 | 2 anni | |
| Tom Paulson | M | 77 | - | |
| Ramin Najafi | M | 65 | 15 anni | |
| James New | M | 70 | 1 anni | |
| Michael L. Babich | M | 47 |
InSys Therapeutics, Inc. /Old/
 InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 8 anni |
| Mark M. Sieczkarek | M | 69 | 5 anni | |
| Martin K. McCarthy | M | 65 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ.
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 5 anni |
| Steven J. Meyer | M | 67 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 12 anni |
| John J. McGovern | M | - | 2 anni | |
| John O'Reilly | M | 81 |
NovaCal Pharmaceuticals, Inc.
 NovaCal Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services NovaBay Pharmaceuticals, Inc. used to manufacture pharmaceutical products. It was clinical-stage pharmaceutical company developed a new class of compounds. The company was founded by Anthony Dailley and was headquartered in Emeryville, CA. | 6 anni |
| Bob Tufts | M | 90 |
NovaCal Pharmaceuticals, Inc.
NovaCal Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services NovaBay Pharmaceuticals, Inc. used to manufacture pharmaceutical products. It was clinical-stage pharmaceutical company developed a new class of compounds. The company was founded by Anthony Dailley and was headquartered in Emeryville, CA. | 13 anni |
| Jerrold Dotson | M | 71 | 8 anni | |
| Laurence P. Birch | M | 64 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 4 anni |
| Tony D. S. Wicks | M | 85 |
NovaCal Pharmaceuticals, Inc.
NovaCal Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services NovaBay Pharmaceuticals, Inc. used to manufacture pharmaceutical products. It was clinical-stage pharmaceutical company developed a new class of compounds. The company was founded by Anthony Dailley and was headquartered in Emeryville, CA. | 20 anni |
| Behzad Khosrovi | M | 80 | 17 anni | |
| Anthony Dailley | M | 69 |
NovaCal Pharmaceuticals, Inc.
NovaCal Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services NovaBay Pharmaceuticals, Inc. used to manufacture pharmaceutical products. It was clinical-stage pharmaceutical company developed a new class of compounds. The company was founded by Anthony Dailley and was headquartered in Emeryville, CA. | 14 anni |
| Susanne Wilke | M | 61 | 1 anni | |
| Bernard A. Fox | M | - |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ.
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 7 anni |
| Matthew M. Loar | M | 61 | - | |
| Jason Raleigh | M | 47 | 4 anni | |
| T. Alex McPherson | M | 85 | 10 anni | |
| Charles J. Cashion | M | 73 | 10 anni | |
| Gail Maderis | F | 66 | 10 anni | |
| Acquilar Rahman | M | - |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 21 anni |
| Keith R. Bley | M | 64 |
Syntex Corp.
| 9 anni |
| Richard C. Dietz | M | - | - | |
| Kenneth J. Gorelick | M | - | 1 anni | |
| Shahid Ali | M | - |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 10 anni |
| Massimo Radaelli | M | 65 | 2 anni | |
| James R. Gottlieb | M | 76 | 7 anni | |
| Todd Zavodnick | M | 52 | 3 anni | |
| Audrey Kunin | M | 65 | 2 anni | |
| Lynn Christopher | F | 69 | - | |
| Brian Tambi | M | 78 | - | |
| John V. Talley | M | 68 |
Penwest Pharmaceuticals Co.
 Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | - |
| Andrew Jones | M | 53 | 3 anni | |
| Tod Hamachek | M | 78 |
Penwest Pharmaceuticals Co.
Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | 8 anni |
| Pierre LaPalme | M | 83 | 9 anni | |
| Dileep Bhagwat | M | 73 |
Penwest Pharmaceuticals Co.
Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | 5 anni |
| Anthony Cataldo | M | 73 | 2 anni | |
| Guillermo A. Herrera | M | 70 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 2 anni |
| Jon W. McGarity | M | 82 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 1 anni |
| Ronald E. Pauli | M | 63 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 1 anni |
| Jay M. Haft | M | 89 | 3 anni | |
| Frank C. Becker | M | 88 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ.
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 7 anni |
| William A. Fletcher | M | 75 | - | |
| John H. Abeles | M | 78 | 2 anni | |
| James Wilson | M | 80 |
Syntex Corp.
| 3 anni |
| Kevin Tang | M | 57 |
Penwest Pharmaceuticals Co.
Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | 1 anni |
| Lawrence Kenyon | M | 58 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 6 anni |
| Sam Kongsamut | M | - | - | |
| Paula D. Buckley | F | - |
Penwest Pharmaceuticals Co.
Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | - |
| Irwin A. Heyman | M | 82 |
Syntex Corp.
| 10 anni |
| Jeffrey Sherman | M | 69 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 7 anni |
| Ira Weisberg | M | 75 | - | |
| Rolf H. Henel | M | 86 |
Penwest Pharmaceuticals Co.
Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | - |
| Ronald G. Eidell | M | 80 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | - |
| Glenn Moro | M | - | - | |
| Greg Miller | M | - | - | |
| Gregory P. Young | M | 70 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 1 anni |
| Harold E. van Wart | M | 76 |
Syntex Corp.
| 8 anni |
| Yasuhiro Hashimoto | M | 68 |
Syntex Corp.
| - |
| Wang Xu | F | 41 | - | |
| Mark T. Edgar | M | - |
Syntex Corp.
| 16 anni |
| Russell A. Hoon | M | - | - | |
| Amy O'Donnell | M | - |
Penwest Pharmaceuticals Co.
Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | - |
| Jim O'Shea | M | 74 |
Penwest Pharmaceuticals Co.
Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | - |
| Steven B. Binion | M | 71 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | - |
| Paul F. Hayes | M | 68 |
Penwest Pharmaceuticals Co.
Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | - |
| Ken Krantz | M | - | - | |
| David J. Morgans | M | 71 |
Syntex Corp.
| 12 anni |
| Amale Hawi | M | 70 |
Penwest Pharmaceuticals Co.
Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | - |
| Mark Brian Anderson | M | 66 | - | |
| Neil William Flanzraich | M | 80 |
Syntex Corp.
| 13 anni |
| Virgil Thompson | M | 84 |
Syntex Corp.
| 24 anni |
| Fred Kurland | M | 74 |
Syntex Corp.
| 14 anni |
| George T. Jue | M | 71 |
Syntex Corp.
| 13 anni |
| David Meeker | M | 69 |
Penwest Pharmaceuticals Co.
Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | 3 anni |
| Hugo Madden | M | 75 |
Syntex Corp.
| 18 anni |
| John N. Staniforth | M | 70 |
Penwest Pharmaceuticals Co.
Penwest Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY. | - |
| Bonnie Charpentier | M | 72 |
Syntex Corp.
| 4 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Paul Freiman
- Contatti personali
